


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. VPI/SW/002 CIP2 FWC DIV2 CON	SERIAL NO. 09/670,106
	APPLICANT P. Sleath et al.	CONFIRMATION NO. 5809
	FILING DATE September 26, 2000	GROUP 1614



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
cm	4,636,492	1/13/87	Kettner et al.	514	18	
	4,644,055	2/17/87	Kettner et al.	530	330	
	4,652,552	3/24/87	Kettner et al.	514	18	
	4,808,523	2/28/89	Revel et al.	435	69.51	
	5,104,853	4/14/92	Beason et al.	514	12	
	5,225,354	7/6/93	Knowles et al.	436	548	
	5,304,481	4/19/94	Davies et al.	435	196	
	5,756,465	5/26/98	Sleath et al.	514	17	

RECEIVED  
JUL 31 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 272 671	6/24/88	EP				
	0 533 350	3/24/93	EP				
cm	WO91/15577	10/17/91	WIPO				
cm	WO93/05071	3/18/93	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
cm	Beuscher et al. IL-1 beta is secreted by activated murine macrophages as biologically inactive precursor. <i>J. Immunol.</i> <b>144</b> , 2179 (1990).
	Black et al. Generation of biologically active interleukin-1 $\beta$ by proteolytic cleavage of the inactive precursor. <i>J. Biol. Chem.</i> <b>263</b> , 9437 (1988).
	Black et al. A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin 1 $\beta$ . <i>J. Biol. Chem.</i> <b>264</b> , 5323 (1989).
	Black et al. Activation of interleukin-1 $\beta$ by a co-induced protease. <i>FEBS Letts.</i> <b>247</b> , 386 (1989).
	Black et al. Identification of a protease that processes interleukin-1 $\beta$ . In <i>Molecular and Cellular Biology of Cytokines</i> . (J. Oppenheim, M. Powanda, M. Kluger, C. Dinarello, Eds.) pp. 69-74, Wiley-Liss, New York, NY (1990).

EXAMINER


cm

DATE CONSIDERED

6/16/04  
4-16-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
VPI/SW/002 CIP2 FWC  
DIV2 CONSERIAL NO.  
09/670,106INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
P. Sleath et al.CONFIRMATION  
NO. 5809FILING DATE  
September 26, 2000GROUP  
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER  
INITIAL

cm

Black et al. Purification and molecular cloning of the IL-1 $\beta$  processing enzyme. *J. Cell. Biochem. Supp.* **15G**, CH 201 (1991).

cm

Black et al. The proteolytic activation of Interleukin-1b. In *Progress in Inflammation Research and Therapy*. (N. Ackerman, R. Bonney, A. Welton, Eds.) pp. 85-89 Birkhauser Verlag, Basel (1990).

cm

CAPLUS DN 116 50949, Rosenthal et al. *J. Clin. Invest.* **88**, 1467 (Abstract) (1991).

cm

CAPLUS DN 118: 208112, Thornberry et al. *Nature* **35**, 768 (Abstract) (1992).

cm

Casano et al. The structure and complete nucleotide sequence of the murine gene encoding interleukin-1 $\beta$  converting enzyme (ICE). *Genomics* **20**, 474 (1994).Cerretti et al. Molecular cloning of the IL-1 $\beta$  processing enzyme. *J. Cell. Biol. Supp.* **F15**, P506 (1991).Cerretti et al. Molecular cloning of the IL-1 $\beta$  processing enzyme. *Cytokine* p. 137 (1991).Cheremisinoff et al. (eds). *Biotechnology Applications and Research*, Technomics Publishing Co, Inc. pp. 21, 541-557 (1985).Dower et al. The interleukin-1 system: Receptors, ligands and signals. *Chem. Immunol.* **51**, 33 (1992).Dreyer et al. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. *Proc. Natl. Acad. Sci. USA* **86**, 9752 (1989).Hazuda et al. The kinetics of interleukin 1 secretion from activated monocytes. *J. Biol. Chem.* **263**, 8473 (1988).Howard et al. IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 $\beta$  precursor at two distinct sites and does not cleave 31-kDa IL-1a. *J. Immunol.* **147**, 2964 (1991).Kitada et al. New peptide models for studying racemization. *Chem. Pharm. Bull.* **26**, 585 (1978).Knittel et al. Stimulation of insulin secretion from pancreatic islets by the cholecystokinin-tetrapeptide analogs Trp-Pro-Asp-Phe-NH<sub>2</sub> and Trp-Pro-Asp-Phe(4'-NO<sub>2</sub>)-NH<sub>2</sub>. *Pept. Res.* **3**, 224 (1990).Koga et al. Comparative study on specifics of rat cathepsin L and papain: amino acid differences as substrate binding sites are involved in their specificities. *J. Biochem.* **108**, 976 (1990).Kostura et al. Identification of a monocyte specific pre-interleukin 1 $\beta$  convertase activity. *Proc. Natl. Acad. Sci. USA* **86**, 5227 (1989).Lee et al. Generation of cDNA probes directed by amino acid sequence: Cloning of urate oxidase. *Science* **239**, 1288 (1988).Malek et al. Amino acid sequence of an invertebrate FBP aldolase (from *Drosophila melanogaster*). *Biochem. Biophys. Res. Comm.* **126**, 195 (1985).

RECEIVED

JUL 31 2002

EXAMINER


cm

DATE CONSIDERED TECH CENTER 1600/2900  
4-16-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

6/16/04

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
VPI/SW/002 CIP2 FWC  
DIV2 CONSERIAL NO.  
09/670,106INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
P. Sleath et al.CONFIRMATION  
NO. 5809FILING DATE  
September 26, 2000GROUP  
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER  
INITIAL

Cm

March et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. *Nature* **315**, 641 (1985).McQuade et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. *Science* **247**, 454 (1990).Mosley et al. Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 alpha and 1 beta. *Proc. Natl. Acad. Sci. USA* **84**, 4572 (1987).Rasnick. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. *Anal. Biochem.* **149**, 461 (1985).

Sigma catalog. pp. 294-295, 312, 351-352 (1989).

Sleath, P. et al. Substrate specificity of the protease that processes human interleukin-1 $\beta$ . *J. Biol. Chem.* **265**, 14526 (1990).Smith et al. Visualization of time-dependent inactivation of human tumor cathepsin B isoenzymes by a peptidyl fluoromethyl ketone using a fluorescent print technique. *Anticancer Res.* **8**, 525 (1988).Stein. Catalysis by human leukocyte elastase 4. Role of secondary subsite interactions. *J. Am. Chem. Soc.* **107**, 5767 (1985).Suggs, S. et al. Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for human  $\beta$ 2-microglobulin. *Proc. Natl. Acad. Sci. USA* **78**, 6613 (1981).Tomasselli et al. Substrate analogue inhibition of active site titration of purified recombinant HIV-1 protease. *Biochemistry* **29**, 264 (1990).Van Noorden et al. Cysteine proteinase activity in arthritic rat knee joints and the effects of a selective systemic inhibitor, Z-Phe-Ala-CH<sub>2</sub>F. *J. Rheumatol.* **15**, 10 (1988).Woessner. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. *FASEB J.* **5**, 2145 (1991).Young et al. Human interleukin 1 beta is not secreted from hamster fibroblasts constitutively from a transfected cDNA. *J. Cell. Biol.* **107**, 447 (1988).Young et al. Yeast RNA polymerase II genes: Isolation with antibody probes. *Science* **222**, 778 (1983).

RECEIVED

JUL 31 2002

TECH CENTER 1600/2900

EXAMINER

Cm

DATE CONSIDERED

6-16-04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.